2026年过敏性哮喘药物品牌推荐：精准控哮，长效无忧

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The competitive landscape is evolving, with multinational companies like GlaxoSmithKline and AstraZeneca facing challenges from local firms that are leveraging policy changes and technological advancements to capture market share [16][17] Market Background - The report outlines the definition of allergic asthma, emphasizing its association with Th2-mediated immune responses and its links to other allergic conditions [5] - The market is experiencing a profound transformation, moving from traditional inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to targeted therapies that address specific inflammatory pathways [6] Market Status - The market is characterized by a strong demand for innovative treatments, with over 40 million patients in China and nearly one million new cases annually, leading to a significant increase in drug demand [7][8] - The supply side includes a variety of treatment options, including chemical drugs, allergen immunotherapy (AIT), and biologics, with a focus on improving patient adherence and treatment outcomes [9][10] Market Competition - The competitive assessment includes product innovation capability, market share, and strategic research and development (R&D) positioning as key dimensions for evaluating leading companies in the allergic asthma drug sector [13][14][15] - The report identifies ten recommended brands, highlighting their innovative products and market positions, such as Mabtech's CMAB007 and AstraZeneca's inhalation solutions [21][22][24] Development Trends - The report discusses several key trends shaping the future of the allergic asthma drug market, including the acceleration of precision medicine, advancements in inhalation device technology, and the impact of policy reforms on market dynamics [32][33][34][36][37] - Digitalization and the integration of healthcare services are expected to enhance patient management and treatment adherence, creating a more comprehensive ecosystem for asthma care [37]